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 2 
Abstract 1 
The human pathogen enteropathogenic Escherichia coli (EPEC), as well as the mouse 2 
pathogen Citrobacter rodentium, colonize the gut mucosa via attaching and effacing lesion 3 
formation and cause diarrheal diseases. EPEC and C. rodentium type III secretion system 4 
(T3SS) effectors repress innate immune responses and infiltration of immune cells. 5 
Inflammatory caspases such as caspase-1 and caspase-4/11 are crucial mediators of host 6 
defense and inflammation in the gut via their ability to process cytokines such as IL-1 and 7 
IL-18. Here we report that the effector NleF binds the catalytic domain of caspase-4 and 8 
inhibits its proteolytic activity. Following infection of intestinal epithelial cells (IECs) EPEC 9 
inhibited caspase-4 and IL-18 processing in an NleF-dependent manner. Depletion of 10 
caspase-4 in IECs prevented the secretion of mature IL-18 in response to infection with 11 
EPECΔnleF. NleF-dependent inhibition of caspase-11 in colons of mice prevented IL-18 12 
secretion and neutrophil influx at early stages of C. rodentium infection. Neither wild-type C. 13 
rodentium nor C. rodentiumΔnleF triggered neutrophil infiltration or IL-18 secretion in 14 
Cas11 or Casp1/11 deficient mice. Thus, IECs play a key role in modulating early innate 15 
immune responses in the gut via a caspase-4/11 - IL-18 axis, which is targeted by virulence 16 
factors encoded by enteric pathogens. 17 
 3 
Introduction 18 
Central to the infection strategy of the extracellular pathogens enteropathogenic Escherichia 19 
coli (EPEC), enterohaemorrhagic E. coli (EHEC)(1) and Citrobacter rodentium(2) is injection 20 
of type III secretion system effectors into intestinal epithelial cells (IECs) where they target 21 
diverse signalling pathways, particularly innate immune signaling. NleC and NleD are Zn-22 
dependent endopeptidases that specifically cleave and disable RelA (p65) and JNK, 23 
respectively, thus blocking NF-κB and AP-1 activation(3). NleE is a methyltransferase that 24 
specifically modifies a cysteine in the zinc finger domain of TAB2 and TAB3 thus also 25 
blocking NF-kB signalling(4). NleB, which also inhibits NF-kB, has an N-acetylglucosamine 26 
transferase activity that specifically modifies Arg 117 in the death domain of FADD(5,6) and 27 
NleH is a serine/threonine kinase that inhibits the RPS3/NF-κB pathway via phosphorylation 28 
of CRKL (v-Crk sarcoma virus CT10 oncogene-like protein)(7).  29 
Inhibition of innate immunity by EPEC and EHEC is needed to counter its activation by the 30 
T3SS, flagellins and lipopolysaccharides (LPS), which are readily detected by sensors and 31 
receptors in mammalian hosts. In response to infection, some sensors assemble 32 
macromolecular complexes called inflammasomes to stimulate the protease activity of 33 
caspase-1. The proteolytic processing and release of interleukin (IL)-1 and IL-18, and the 34 
induction of pyroptotic cell death triggered by caspase-1 can prevent the establishment and 35 
spread of microbial pathogens(8,9). In addition, the single mouse caspase-11 and the related 36 
human caspase-4 and caspase-5 act as cytosolic receptors, which bind LPS directly via their 37 
N-terminal caspase activation and recruitment domains (CARD, p22 domain). LPS binding 38 
induces oligomerization and autoproteolytic activation of caspase-4/5/11 into their active 39 
p20/p10 fragments and subsequent pyroptotic lysis of bacterially infected host cells(10). In 40 
human and mouse phagocytic cells LPS is detected by caspase-4/11, which stimulate 41 
 4 
caspase-1-dependent maturation of IL-1 and IL-18 via the NLRP3-ASC inflammasome(11-42 
13)
. However, in IECs caspase-4/11 acts independently of NLRP3 and caspase-1 to directly 43 
process IL-18 and induce pyroptosis during Salmonella infection(14). Therefore the detection 44 
of Gram-negative bacteria by IECs markedly contrasts that in myeloid cells. However, unlike 45 
Salmonella, which are intracellular pathogens, extracellular pathogens use T3SS to prevent 46 
death pathways in host cells to which they intimately adhere(5,6,15). This suggests that EPEC, 47 
EHEC and C. rodentium might manipulate caspase-4/11 and/or inflammasome pathways in 48 
IECs. 49 
Previous work on C. rodentium infections in mice showed that loss of inflammasome 50 
signaling related genes such as Nlrp3, Nlrc4, Casp1, Casp11, Il1 and Il18 results in 51 
enhanced morbidity and inflammatory disease, whereas wild-type mice clear the pathogen 52 
within 14-21 days(16,17). Detection of C. rodentium, EHEC and EPEC in myeloid cells has 53 
also been studied previously, and a recent report identified the EPEC NleA T3SS effector 54 
protein as an inhibitor of NLRP3-caspase-1 inflammasomes(18). However, as IECs use non-55 
canonical, NLRP3- and caspase-1-independent mechanisms to detect bacteria, we 56 
hypothesized that EPEC and C. rodentium subvert caspase-4/11 action in IECs upon initial 57 
attachment. Here we report that bacterial T3SS effector NleF is a potent inhibitor of 58 
mammalian caspase-4/11 and thus prevents IL-18 secretion from IECs in vitro, and blocks 59 
caspase-11 – IL-18 mediated neutrophil influx during infection in vivo. 60 
 5 
Results  61 
NleF binds human caspase-4  62 
The highly conserved effector NleF was previously reported to bind the active site and to 63 
inhibit the activity of caspase-9, caspase-8 and caspase-4, however, whether NleF affects 64 
inflammasome signaling and the innate immune response to bacterial infection in vivo has not 65 
been tested(19). By employing a yeast-2-hybrid screen (Table S1) and a direct yeast-2-hybrid 66 
(DYH) assay (Fig. 1A) we confirmed that human caspase-4 is an interacting partner of EPEC 67 
NleF (NleFEPEC). Truncation analyses revealed an interaction between NleFEPEC and the p30 68 
catalytic domain of caspase-4 (Fig. 1B). Deletion of four C-terminal residues in NleFEPEC 69 
(NleF1-185_EPEC) abrogates its binding to caspase-9(19), and similar defects were seen in 70 
binding to caspase-4 (Fig. 1B). Mutation of the substrate-binding pocket of caspase-4 71 
(R152A, W313A and R314A) also abolished NleF-caspase-4 interaction (Fig. 1B). To 72 
confirm that the binding is direct, the caspase-4 p20 subunit (22 kDa; His tagged), p10 73 
subunit (10 kDa) and NleFEPEC (65 kDa; MBP fusion) were co-expressed, purified by tandem 74 
affinity chromatography and analyzed by gel filtration. Three chromatographic peaks 75 
corresponding to free MBP-NleFEPEC, free His-p20, and a complex containing NleFEPEC, p20 76 
and p10 subunits were observed (Fig. 1C). NleFEPEC and caspase-4 subunits co-purified and 77 
co-eluted as a macromolecular complex with an apparent molecular weight (MW) of ~230 78 
kDa (Fig. 1C-D). 79 
NleF inhibits human caspase-4 and mouse caspase-11 80 
Recombinant caspase-4 underwent auto-proteolytic activation presumably as a consequence 81 
of LPS binding when purified from E. coli. Wild-type caspase-4, but not a catalytic dead 82 
mutant (caspase-4C285S), underwent auto-proteolysis to the active p20 form and hydrolyzed 83 
the caspase-4 fluorogenic substrate peptide (Ac-LEVD-AFC; Fig. 2A). Recombinant 84 
NleFEPEC inhibited the activity of caspase-4 in a dose-dependent manner with an IC50 of 5 nM 85 
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(Fig. 2B), comparable to 14 nM previously measured for NleFEHEC by Blasche et al.(19).  86 
Despite not binding caspase-4 in DYH, NleF1-185_EPEC, which was pulled down with caspase-87 
4 at low levels (data not shown), was able to inhibit caspase-4 activity although at an IC50 of 88 
25.5 nM (Fig. 2B). C. rodentium NleF (NleFCR), which shares 84% amino acid identity with 89 
NleFEPEC, strongly inhibited the proteolytic activity of mouse caspase-11 (IC50 of 13 nM; Fig. 90 
2C-D) revealing an evolutionarily conserved functional property. Importantly, we found that 91 
NleFEPEC inhibits caspase-4 more efficiently than NleFCR (Fig. 2C), while NleFCR inhibits 92 
caspase-11 more efficiently than caspase-4 (Fig. 2F). 93 
NleF inhibits h-caspase-4 activation during infection 
 
94 
To investigate if NleFEPEC targets caspase-4 during infection of human IECs, Caco-2 cells 95 
were infected with the wild-type (WT) EPEC and EPECΔnleF; both strains adhered to the 96 
cultured cells equally (Fig. 3A). However, while secreted caspase-4 was absent following 97 
infection with WT EPEC, the active p30 fragment of caspase-4 was found in the supernatants 98 
of cells infected with EPECΔnleF (Fig. 3B). Addition of the caspase-4 inhibitor Ac-LEVD-99 
CHO complemented the EPECΔnleF phenotype in a dose dependent manner (Fig. 3B). 100 
NleFEPEC did not affect the expression of pro-IL-18, which was similar in uninfected cells and 101 
those infected with all the EPEC strains (Fig. 3C). While secretion of pro-IL-18 was detected 102 
upon infection with WT EPEC and EPECΔnleF, pro-IL-18 was only processed into the active 103 
form following infection with EPECΔnleF (Fig. 3D). Secretion of mature IL-18 (mIL-18), 104 
induced by EPECΔnleF, was not detected when this strain was complemented with a plasmid 105 
encoding NleFEPEC (pNleFEPEC) (Fig. 3D).  106 
To confirm that inhibition of caspase-4 by NleF was sufficient to block processing of IL-18, 107 
we generated Caco-2 cells depleted of caspase-4 using miRNA30E based stable shRNA 108 
expression (Fig. 4A). EPECΔnleF infection of Caco-2 cells silenced for caspase-4 expression 109 
 7 
(C4) did not secrete mIL-18, as measured by both western blotting (Fig. 4B) and ELISA (Fig. 110 
4C), clearly pointing to a requirement of caspase-4 in IL-18 processing during EPEC 111 
infection of IECs. Importantly, no cell death was detectable by measuring LDH release or PI 112 
uptake following infection of control or caspase-4-depleted Caco-2 cells (Fig. 4D); this is 113 
likely due to EPEC T3SS effectors (e.g. NleH, NleB), which inhibit cell death(5,6,15). Thus, in 114 
human IECs, pro-IL-18 processing during EPEC infection is caspase-4 dependent and the 115 
bacterially injected NleF specifically inhibits this process.   116 
C. rodentium inhibits IL-18 secretion in vivo in an NleFCR-dependent manner 117 
To test the role of NleF during infection in vivo we infected C57BL/6 mice with WT C. 118 
rodentium, C. rodentiumΔnleF or C. rodentiumΔnleF complemented with pnleFCR. 119 
Colonization (Fig. 5A) and colonic crypt hyperplasia (Fig. 5B) were similar between the 120 
different C. rodentium strains (Fig. 5). We quantified levels of IL-18 and IL-1 secreted from 121 
colonic explants, and the inflammasome-independent chemokine CXCL1 as a control, on 122 
days 4 and 8 post-infection (p.i.). On day 4 post infection of C57BL/6 mice with C. 123 
rodentiumΔnleF we detected a significantly increased colonic secretion of IL-18, while 124 
mock-infected (PBS) or WT C. rodentium-infected colons released similarly low levels of IL-125 
18 (Fig. 5C). Complementing the C. rodentium ΔnleF mutant with a plasmid encoding 126 
NleFCR restored the inhibition of IL-18 secretion (Fig. 5C); secreted IL-1β was below the 127 
detectable limit (data not shown). Secretion of CXCL1 was similar in colons extracted from 128 
mice treated with PBS or infected with WT C. rodentium or C. rodentiumΔnleF (Fig. 5D). 129 
Complementing the C. rodentium ΔnleF mutant with a plasmid encoding NleFCR resulted in a 130 
significantly increased CXCL1 secretion (Fig. 5D), which is consistent with our recent 131 
finding that over expression of NleFEPEC activates NF-κB in cultured cells(20). Importantly, 132 
NleF-dependent inhibitory effects were only observed early during infection (day 4 p.i.), and 133 
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IL-18 secretion was similar following WT C. rodentium or C. rodentium ΔnleF infection on 134 
day 8 p.i. (Fig. 5E).  135 
To validate that NleFCR inhibits IL-18 secretion via the inflammasomes, we first infected 136 
Casp1/11 deficient mice with C. rodentium and C. rodentiumΔnleF. As expected, loss of 137 
Casp1 and Casp11 abolished IL-18 secretion from colonic explants after infection with WT 138 
C. rodentium or C. rodentium ΔnleF (Fig. 5C); CXCL1 secretion was similar in Casp1/11-/- 139 
mice infected with the two strains (data not shown). In order to confirm that the phenotype 140 
was due to caspase-11, we next infected Casp11-/- mice with C. rodentium or C. rodentium 141 
ΔnleF. This showed that while WT C. rodentium and C. rodentiumΔnleF colonized the 142 
Casp11-/- mice at comparable levels (Fig. 5F), secretion of IL-18 was extremely low and 143 
similar to that in Casp1/11-/- mice (Fig. 5C). We therefore concluded that caspase-11 is 144 
responsible for secretion of IL-18 following infection with C. rodentium nleF. 145 
IL-18 is essential for the recruitment of neutrophils early during C. rodentium infection  146 
As IL-18 facilitates neutrophil and leukocyte recruitment to sites of inflammation(21), we 147 
investigated the effect of NleFCR on immune cell recruitment. Infection of C57BL/6 mice for 148 
4 days with C. rodentiumΔnleF resulted in a significant increase in neutrophil recruitment in 149 
comparison to WT C. rodentium-infected or PBS-treated mice (Fig. 6B). Infection with the 150 
C. rodentium ΔnleF pnleFCR strain restored the inhibition of neutrophil recruitment (Fig. 6B). 151 
No significant differences were observed for other myeloid or lymphocyte cell type analyzed, 152 
including macrophages, ILC, B-cells and T-cells (data not shown). Furthermore, correlating 153 
with similar IL-18 secretion, no difference in neutrophil recruitment was observed at day 8 154 
post infection (Fig. 6C), suggesting that NleFCR plays a specific role during early immune 155 
responses to C. rodentium. Enhanced neutrophil influx was Casp1/11 dependent; absence of 156 
these caspases abolished the increase in neutrophil recruitment during infection with C. 157 
rodentiumΔnleF (Fig. 6B). Similar results were obtained following infection of Casp11-/- 158 
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mice (Fig. 6B). Thus NleFCR is a virulence factor responsible for early inhibition of the host 159 
inflammasomes, and that the inflammasome is essential for early neutrophil recruitment in 160 
response to C. rodentium infection.  161 
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Discussion 162 
Inflammasome dependent cytokines and pyroptosis have important antimicrobial 163 
functions(8,9). It is therefore not surprising that pathogenic bacteria have evolved mechanisms 164 
to prevent inflammasome activation(22). For example, Yersinia uses YopK to prevent 165 
detection of its T3SS(22), and bacteria modify their LPS to evade detection by caspase-11(23). 166 
The Shigella flexneri effector OspC3 sequesters caspase-4 activity by binding the caspase-4 167 
p20 subunit to prevent p10 binding and oligomerization(24). Here we demonstrate that a 168 
virulence factor of A/E pathogens, NleF, targets the heterotetramer complex of caspase-4 via 169 
its C-terminal motif, underlining the importance of caspase-4 inhibition during the course of 170 
infection. 171 
In agreement with our biochemical analyses, EPEC was able to inhibit caspase-4 in IECs in 172 
an NleF-dependent manner, while recent reports showed that infection of cultured cells with 173 
either Salmonella or EPEC led to caspase-4 activation(24) and caspase-4-dependent induction 174 
of IL-18 release(14). Taken together, our data suggest that while EPEC can initiate caspase-4 175 
activation and IL-18 processing, NleF dampens this response. Previous studies have shown 176 
that Nlrp3, Nlrc4, Casp1 and Casp11 are important in protection against C. rodentium 177 
infection(16,25). Loss of inflammasome-related genes results in significantly increased C. 178 
rodentium bacterial load in the intestine late in infection, which may partly explain the 179 
enhanced inflammation in inflammasome-deficient mice infected with C. rodentium. Loss of 180 
inflammasome-dependent IL-1 and IL-18 also results in enhanced bacterial burdens at late 181 
stages of infection and susceptibility to C. rodentium infection of Il1b-/- and Il18-/- mice(16). 182 
Our studies establish that NleF functions at early stages of infection of mucosal surfaces by 183 
inhibiting the inflammasome and preventing release of IL-18 by epithelial cells.  184 
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We also found that NleFCR inhibited caspase-11-dependent neutrophil recruitment. IL-18 is a 185 
key regulator of the adaptive immune response, stimulates the migration of innate and 186 
adaptive immune cells(21,26,27), and controls intestinal epithelial cell turnover and protects 187 
against damage in the intestine(28). During the early stages of infection, IL-18 is largely 188 
secreted by epithelial cells(17). Current data(16), including the secretion of IL-1β which is not 189 
expressed in non-hematopoietic cells(29), suggests that at later time points during C. 190 
rodentium infection colonic IL-18 secretion may switch to be myeloid cell dependent(16). 191 
Therefore, myeloid cell secretion of the IL-1 family cytokines may not be subverted by 192 
NleFCR and would become the pre-dominant source of IL-18 and IL-1β at the peak of 193 
infection. Similarly secretion of IL-22 is switched from ILC3 at early phase of infection to 194 
IL-22-producing T cells at later time points (> 7 days)(30). 195 
The study demonstrates a pathway during infection of IECs, which leads to the activation of 196 
caspase-11, secretion of IL-18 and recruitment of neutrophil. In addition, we show that 197 
inhibition of caspase-11 by bacterial NleF blocks this pathway in the host. Our findings are 198 
consistent with the recent study on the epithelial cell caspase-11–IL-18 axis during 199 
Salmonella infection, which reported significant neutrophil influx in infected gall bladder 200 
epithelia of wild-type mice, but no neutrophil influx in Casp11-/- mice(31).  201 
Recent studies have revealed the contribution of non-inflammasome and inflammasome-202 
forming NLRs in the non-hematopoietic compartment for intestinal homeostasis and the host 203 
mediated clearance and protection against enteric pathogens(35). Mice deficient in NLRP6 204 
have impaired goblet cell mucus exocytosis and display a microbiome exposed epithelial cell 205 
layer and persistence of C. rodentium infection(36).  Moreover, NLRP12 is a checkpoint for 206 
non-hematopoietic non-canonical NF-κB activation(37), and acts as a negative regulator of 207 
colitis and colitis-associated colon cancer. Furthermore, IEC-expressed NLRC4 mediates 208 
early innate immune responses against C. rodentium via an unknown mechanism independent 209 
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of IL-1 family cytokine secretion(38). Here we show that the caspase-4/11 dependent IECs 210 
inflammasome is crucial for IL-18 cytokine maturation and the early innate immune response 211 
to EPEC/ C. rodentium.  Consistently with this, Song-Zhao et al.(17) recently suggested, based 212 
on studies of Nlrp3-/- and Asc-/- mice, that early protection to C. rodentium infection is 213 
mediated by IECs independently of NLRP3 activation. Taken together, our study identifies a 214 
fundamental and novel role for the T3SS effector NleF in the pathogenesis and virulence of 215 
A/E pathogens through the inhibition of the newly characterized IECs caspase-4/11 216 
dependent inflammasome.  217 
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Methods 218 
Strains, oligonucleotides, plasmids and antibodies  219 
Strains, plasmids and primers used in this study are listed in Tables S2-S3 respectively. nleF 220 
was amplified from EPEC E2348/69 and C. rodentium ICC169 genomic DNA by PCR. Site-221 
directed mutagenesis was carried out by inverse PCR using KOD Hot Start polymerase and 222 
mismatch primers. All constructs were confirmed by sequencing (GATC biotech). For 223 
Western Blot, Mouse monoclonal anti-caspase-4 clone 4B9 (sc-56056; Santa Cruz), anti-α-224 
Tubulin clone DM1A (T6199), mouse polyclonal antibody anti-caspase-11 p20 clone A-2 225 
(sc-374615; Santa cruz) and anti-pro-IL-18 (CPTC-IL18-1; DSHB), the rabbit monoclonal 226 
anti-IL-18 (PM014; MBL), anti-caspase-5 (4429; Cell signalling) and the rabbit polyclonal 227 
antibody anti-GFP (Ab290; Abcam) were used as primary antibodies. Horse radish 228 
peroxidase (HRP)-conjugated goat anti-rabbit IgG (Fc fragement; catalog no.111-035-008; 229 
Jackson immunoresearch) and HRP-conjugated goat anti-mouse IgG (Fc fragement; catalog 230 
no, 115-035-008; Jackson immunoresearch) were used as secondary antibodies. 231 
Retroviral transductions and stable knockdown cell lines 232 
Micro-RNA30 based (miR-30; Table S1) gene silencing constructs were generated in pMX-233 
CMV-YFP using one-step sequence and ligation independent cloning (SLIC) (36) following 234 
the optimized miR-30E vector design(39). Sequences were as follows: CASP4 - 235 
CGACTGTCCATGACAAGAT; and LacZ (non-targeting negative control) 236 
ACGTCGTATTACAACGTCGTGA. The miR-30E plasmids were transfected using 237 
Lipofectamine 2000 (Invitrogen), along with the packaging plasmids pVSV-G and pCMV-238 
MMLV-pack(40) into HEK293E cells to produce a VSV-G pseudotyped retroviral particles for 239 
240 
directly to pre-seeded Caco-2 TC7 cells. Transduced cells were selected by puromycin 241 
(Gibco Invitrogen) at 10 µg.ml-1 and knockdown was confirmed by western blotting.  242 
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EPEC infection, ELISA and Western blotting  243 
Caco-2 TC7 cells (ATCC) were seeded at 7.5 x104/ml and upon reaching confluence (7 days) 244 
the medium was changed every day for 7 the following 7 days. Before infection the cells 245 
were starved for 3 h in serum free DMEM. Monolayers were infected with primed EPEC(20) 246 
at an MOI of 1:10 for 3 h. The cells were then washed twice in PBS and the medium was 247 
replaced with serum free DMEM-high glucose plus penicillin and streptomycin at 100 U/ml 248 
and 100 μg/ml, respectively. After 1 h cells were washed and either processed for Western 249 
Blot (total IL-18) or incubated for a further 17 h (secreted caspase-4 and IL-18) with or 250 
without Ac-LEVD-CHO (Enzo Lifesciences). Supernatants were collected, cleared by 251 
centrifugation at 13000 rpm at 4 ⁰C for 10 min and precipitated for Western blotting with the 252 
addition of 10 % (v/v) trichloroacetic acid for 17 h at 4 ºC. The concentration of IL-18 in cell 253 
supernatant (MBL) was determined by ELISA according to the manufacturer’s protocol. 254 
Cell adhesion and cytotoxicity assays  255 
Caco-2 TC7 were infected with the WT EPEC, EPEC∆nleF and the complemented strain 256 
(pnleFEPEC) for 3 h. The monolayers were lysed in 1 % PBS/triton X-100 and EPEC 257 
attachment was enumerated by serial dilution on LB-Agar and calculation of colony forming 258 
units (CFU).  259 
Supernatants of uninfected cells or cell infected with EPEC for 21 h were harvested and the 260 
level of LDH release was measured using CytoTox 96® Non-Radioactive Cytotoxicity Assay 261 
(Promega). As a control for total LDH, cell lysis buffer (1 % Triton-X100/ PBS) was added 262 
for 30 min at 37 ºC directly to the medium and cell layer. Absorbance was measured at 490 263 
nm using the FluoStar Omega plate reader and results are displayed as percentage of total 264 
release corresponding to the LDH measured in the supernatant divided by the total LDH.   265 
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Alternatively the media was removed and cell layers were incubated in 3.3 µg/ml propidium 266 
iodide (Invitrogen) in warm PBS (PI/PBS) for 15 min and fluorescence was measured at an 267 
excitation of 510 nm and emission of 610 nm using the FluoStar Omega plate reader. As a 268 
control PI/PBS alone was measured or cell lysis buffer (0.05 % Triton X-100/PBS) 269 
supplemented with 3.3 µg/ml propidium iodide was added for 15 min at 37ºC. Results are 270 
displayed as a percentage of total PI uptake.  271 
Yeast-2-hybrid screen and yeast direct hybrids 272 
A yeast-2-hybrid screen was conducted using pGKBT7-nleFEPEC and the HeLa cell cDNA 273 
Library following the manufacturer’s Handbook (Clontech). AH109 were co-transformed 274 
with pGBT9-bait and pGADT7-prey (Table S3) and plated onto Difco Yeast Nitrogen Base 275 
without amino acids (SD) agar supplemented with 2% glucose, 20 mg/L adenine hemisulfate, 276 
20 mg/L arginine HCl, 20 mg/L histidine HCl monohydrate, 30 mg/L isoleucine, 30 mg/L 277 
lysine HCl, 20 mg/L methionine, 50 mg/L phenylalanine, 200 mg/L threonine, 30 mg/L 278 
tyrosine, 20/L mg uracil, 150 mg/ml valine and lacking tryptophan and leucine (Double 279 
Drop-out; DDO) for selection of transformed clones. Clones positive for both plasmids were 280 
re-streaked on to SD DDO and SD QDO /-His/-Ade supplemented with 40 mg/L x-α-gal (SD 281 
QDO) for selection of positive interactions.  282 
Recombinant Protein expression and purification  283 
E. coli BL21 Star expressing pET28-NleFEPEC (pICC1659), pET28-NleF1-185-EPEC (pICC1660) 284 
and pET28-NleFCR (pICC1839) were cultured for 16 h in LB at 37 ⁰C at 200 rpm. Bacteria 285 
were sub-cultured at 1:100 into 1 L LB supplemented with 50 µg/ml kanamycin and 286 
incubated at 37⁰C at 200 rpm until OD600 of 0.4-0.6. Cultures were then induced with 0.5 287 
mM IPTG for 18 h at 18⁰C. Cells were harvested by centrifugation at 10000 rpm for 20 min 288 
and re-suspended in 30 ml ice cold His-lysis buffer (20 mM Tris-HCl pH 7.9, 0.5 M NaCl, 289 
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and 5 mM Imidazole). The cells were lysed by Emulsiflex following the manufacturer’s 290 
instructions (Emulsiflex-B15; Avestin) and centrifuged at 14000 rpm for a further 30 mins at 291 
4⁰C. Supernatant was removed and applied to 5 ml His resin (Novagen) pre-charged in 5 mM 292 
NiSO4 and pre-equilibrated in His-lysis buffer and rocked at 4⁰C for 1.5 h. Samples were 293 
applied to a Poly-Prep Chromatography column (Qiagen) and flow-through was collected. 294 
The column was washed twice with 20 ml His-lysis buffer and once in 20 ml wash buffer 295 
(Tris-HCl pH 7.9, 0.5 M NaCl, and 60 mM Imidazole). His-tagged fusion proteins were 296 
eluted with 10 x 1 ml elution buffer (His-lysis buffer supplemented with 1 M Imidazole). 297 
Fractions containing His-purified NleF were checked by SDS-PAGE gel electrophoresis and 298 
further purified by size exclusion (Akta prime) with a Superdex75 column (GE Healthcare; 299 
10/300GL).  300 
Co-purification of the caspase-4-NleFEPEC complex 301 
BL21 Star cells were co-transformed with pACYC-DUET-1-CASP4C258S His-p20/p10 and 302 
pMAL-c2x-nleFEPEC. Bacterial pellets were re-suspended in 20mM Tris-HCl pH 7.4, 250 303 
mM NaCl and lysed by sonication and purified by amylose affinity chromatography. 304 
Bacterial lysates were incubated with amylose resin for 1.5 h at 4 C and then washed with 305 
50 ml wash buffer (20 mM Tris-HCl pH 8.0, 250 mM NaCl and eluted with wash buffer 306 
supplemented with 10 mM maltose. The co-elute was dialysed and then purified further by 307 
IMAC talon affinity chromatography, as described previously(41). Complex formation was 308 
analysed by size exclusion (Akta prime) with a Superdex200 column (GE Healthcare) using 309 
the Gel Filtration Markers Kit for Protein Molecular Weights 12,000-200,000 Da (Sigma-310 
Aldrich) to determine complex size. Size exclusion fractions were verified by SDS PAGE gel 311 
and confirmed by Mass spectrometry.  312 
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Caspase activity assays 313 
BL21 star were transformed with pET28a-empty, pET28a-CASP4, pET28a-CASP4 C258S or 314 
pET28a-Casp11. Soluble lysates at 200 µg/ml were incubated with or without 50 µM Ac-315 
LEVD-AFC (Enzo Life Sciences) in 20 mM PIPES, 100 mM NaCl, 10 mM DTT, 1 mM 316 
EDTA, 0.1% CHAPS, 10% sucrose pH 7.2 or 20 mM Tris, 250 mM NaCl pH 7.4 for 317 
caspase-11 and caspase-4, respectively. Purified recombinant His-NleF derivatives were 318 
added at varying concentrations from 50 nM to 1 pM. Fluorescence was measured in 5 min 319 
intervals at 37 ⁰C using an excitation of 410 nm and emission of 520 nm using the FLUOstar 320 
Omega plate reader (BMG Labtech).  321 
Construction of C. rodentium mutant  322 
C. rodentium strain ICC169 ΔnleF (ICC1129) was generated using a modified version of the 323 
lambda red-based mutagenesis system(42). Briefly, the nleF gene and its flanking regions were 324 
PCR-amplified from WT C. rodentium ICC169 genomic DNA using the primers pair NleF-325 
up-Fw/NleF-down-Rv and cloned into pC-Blunt-TOPO vector (Invitrogen). The nleF gene 326 
was then excised using inverse-PCR (primers NleF-up-Rv-BamHI/NleF-down-Fw-BamHI) 327 
and the resulting linear product was BamHI digested, allowing insertion of the non-polar 328 
aphT(43), cassette, resulting in plasmid pICC1674. After verifying for correct orientation of 329 
the kanamycin cassette, the insert was PCR-amplified using NleF-up-Fw and NleF-down-Rv 330 
primers. The PCR products were electroporated into wild type C. rodentium expressing the 331 
lambda red recombinase from pKD46 plasmid. The deletion was confirmed by PCR and 332 
DNA sequencing amongst the kanamycin resistant clones (primers NleF-up-Fw-check and 333 
NleF-down-Fw-check). 334 
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Oral infection of mice 335 
Pathogen-free female C57BL/6 mice were either purchased from Charles River or sourced 336 
from BIME Institut Pasteur. Casp1/11-/- mice were generously provided by Bernhard Ryffel 337 
(TAAM-CDTA, Orelans, France) and Casp11-/- were generously provided by Mohamed 338 
Lamkanfi (Ghent University, Belgium). All animals were housed in individually HEPA-339 
filtered cages with sterile bedding and free access to sterilized food and water. Independent 340 
infection experiments for wild-type C57BL/6, Casp1/11-/- and Casp11-/- mice were performed 341 
using 3 to 8 mice per group. Mice were infected and followed for shedding as described(44). 342 
Briefly, mice were infected via oral gavage with 109 WT C. rodentium or C. rodentium ΔnleF 343 
as described previously. For control, mice were gavaged with sterile PBS. The number of 344 
viable bacteria used as inoculum was determined by retrospective plating onto LB agar 345 
containing antibiotics. Stool samples were recovered aseptically at various time points after 346 
inoculation and the number of viable bacteria per gram of stool was determined by plating 347 
onto LB agar(44).  348 
Sample collection and colonic crypt hyperplasia measurement 349 
Segments of the terminal colon (0.5 cm) of each mouse were collected, flushed and fixed in 350 
10% neutral buffered formalin. Formalin fixed tissues were then processed, paraffin-351 
embedded, sectioned at 5 μm and stained with haematoxylin and eosin (H&E) using standard 352 
techniques. H&E stained tissues were evaluated for colonic crypt hyperplasia microscopically 353 
without knowledge of the treatment condition used in the study and the length of at least 100 354 
well-oriented crypts from each section from all of the mice per treatment group (n=4-6) were 355 
evaluated. H&E stained tissues were imaged with an Axio Lab.A1 microscope (Carl Zeiss 356 
MicroImaging GmbH Germany), images were acquired using an Axio Cam ERc5s colour 357 
camera, and computer-processed using AxioVision (Carl Zeiss MicroImaging GmbH, 358 
Germany). 359 
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Sample collection for cytokine analysis and flow cytometry  360 
Isolation of colonic cells and flow cytometry were performed as described(44). After a PBS 361 
wash, the 5th cm of the distal colon was incubated in RPMI containing penicillin, 362 
streptomycin, gentamicin and FBS at 37°C for 24 h. The concentrations of IL-18 363 
(eBioscience, #BMS618/3), IL-1β and KC (CXCL1; R&D Systems) were determined by 364 
ELISA according to the manufacturer’s protocols.  365 
Statistics 366 
All data was analyzed using GraphPad Prism software, using the Mann-Whitney test and 367 
represented as the mean +/- standard error of mean or standard deviation. A P value less than 368 
0.05 (P<0.05) was considered statistically significant.  369 
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Figure legends 517 
Fig. 1. NleF  binds caspase-4. (A) A direct yeast two hybrid assay revealed that NleFEPEC, 518 
but not NleF1-185_EPEC, interacts with full-length and p30 caspase-4. (B) Substitution of amino 519 
acids R152A, W313A and R314A within the putative caspase-4 substrate domain abrogated 520 
the interaction with  NleFEPEC. (C) Fractions of size exclusion of the chromatographic profile 521 
of MBP-NleFEPEC and His-p20/p10 caspase-4 purified by amylose and talon affinity 522 
chromatography and (D) analyzed by SDS-PAGE gel electrophoresis, revealed that NleFEPEC 523 
and caspase-4 subunits co-purified and co-eluted as a macromolecular complex at a MW of 524 
~230 kDa.  525 
 526 
Fig. 2. NleF inhibits caspase-4 activity. (A) Recombinant caspase-4, but not caspase-4C258S, 527 
is auto-activated (western blot) and cleaves the reporter Ac-LEVD-AFC. Results are plotted 528 
as relative fluorescence units (RLU) minus background (No Ac-LEVD-AFC) over time 529 
(min). (B) Dose-dependent inhibition of caspase-4 Ac-LEVD-AFC cleavage by recombinant 530 
NleFEPEC, and NleF1-185_EPEC (shown by Coomassie stained gel). (C) NleFEPEC (10 nM) 531 
inhibits the activity of caspase-4 more efficiently than NleFCR (10nM) after 30 min incubation 532 
in the presence of Ac-LEVD-AFC. (D) Recombinant caspase-11 is auto-activated (western 533 
blot) and cleaves the reporter Ac-LEVD-AFC. (E) Dose dependent inhibition of caspase-11 534 
activity by recombinant NleFCR (shown by Coomassie stained gel). (F) NleFCR (50 nM) 535 
inhibits the activity of caspase-11 more efficiently than NleFEPEC (50nM) after 30 min 536 
incubation in the presence of Ac-LEVD-AFC.  Results are expressed as a percentage of wild-537 
type caspase-4 or caspase-11 RLU/min from at least two independent experiments. * 538 
indicates P<0.05. 539 
 540 
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Fig. 3. NleF inhibits secretion of caspase-4 and IL-18 during EPEC infection. (A) 541 
Infection of polarized Caco-2 cells with WT EPEC, EPEC∆nleF or the complemented strain 542 
(pnleFEPEC) revealed similar levels of cell adhesion (3 h post infection). (B) Caco-2 cells 543 
were infected with WT EPEC or EPECΔnleF in the absence or presence of the inhibitor Ac-544 
LEVD-CHO (total 21 h). Immunoblotting of supernatants (SN) revealed that EPEC inhibits 545 
secretion of active caspase-4 (~28 kDa) in an NleFEPEC-dependent manner, assessed by 546 
western blots (upper panel) and quantified by densitometry of multiple experiments (lower 547 
panel). (C) Infection of Caco-2 cells with WT EPEC, EPECΔnleF or complemented 548 
EPECΔnleF (pnleFEPEC) had no effect on the levels of total IL-18 at 4 h p.i. (D) NleF is 549 
essential for inhibition of IL-18 secretion from infected Caco-2 cells (21 h post infection). 550 
 551 
Fig. 4. NleFEPEC inhibits IL-18 secretion in an caspase-4 dependent manner. (A) Western 552 
blots showing knockdown of caspase-4, but not capsapse-5, by miRNA30E. (B) Infection of 553 
Caco-2 cells (21 h) depleted of caspase-4 (C4) revealed that it is essential for IL-18 554 
processing in response to infection with EPECΔnleF, assessed by western blots (upper panel) 555 
and quantified by densitometry of two independent experiments (lower panel). (C) ELISA 556 
from two biological repeats showing specific secretion of IL-18 from control (YFP), but not 557 
from C4, Caco-2 cells infected for 21 h with EPECΔnleF. (D) EPEC does not trigger LDH 558 
release or PI uptake during infection (21 h) of control or C4 Caco-2 cells, results are 559 
represented as a percentage of total uptake or total release and are an average of two 560 
biological repeats carried out in triplicate. * indicates P<0.05. 561 
 562 
Fig. 5. NleFCR inhibits colonic IL18 secretion 4 days p.i. WT C. rodentium, C. 563 
rodentiumΔnleF and the complemented strain (ΔnleF pnleFCR) similarly colonized and 564 
 30 
triggered colonic hypoplasia in C57BL/6 mice (A and B). Each dot in B represents an 565 
individual measurement of crypt length (from at least 20 measurements per section per 566 
mouse), and horizontal bars represent mean values.  Significant increase in secreted IL-18, 567 
measured by ELISA, was seen specifically following infection of C57BL/6 with C. 568 
rodentiumΔnleF (day 4), but not following infection of either Casp1/11-/-  or Casp11-/-  mice 569 
(day 4) (C) or C57BL/6 (day 8) (E). Secreted CXCL1 was found in similar levels, except for 570 
the complemented strain, which triggered greater secretion of CXCL1 (D). No difference in 571 
colonization of Casp11-/- mice was seen following infection with WT C. rodentium or C. 572 
rodentiumΔnleF (E). * indicates P<0.05. 573 
 574 
Fig. 6. NleFCR inhibits colonic neutrophil recruitment 4 days p.i. C57BL/6, Casp1/11-/- 575 
and Casp11-/- mice were infected with WT C. rodentium, C. rodentiumΔnleF or 576 
complemented C. rodentiumΔnleF (∆nleF pnleFCR). (A) Representative image of flow 577 
cytometry gating strategy for neutrophils (CD11b+Ly6G+) of control (PBS) and infected 578 
C57BL/6 mice. The number of neutrophils (CD11b+Ly6G+) present within the myeloid gate 579 
was counted from C57BL/6  (B-C, days 4 and 8 post infection), Casp1/11-/- or Casp11-/- (B, 580 
day 4 post infection) mice (at least six mice per condition). * indicates P<0.05.  581 
